1-4 of 4
Jad Othman
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Safety and efficacy of combining midostaurin and gemtuzumab ozogamicin with induction chemotherapy in FLT3 -mutated AML

Open Access
Clinical Trials & Observations
Nigel Russell, Jad Othman, Oliver Cumming, Abin Thomas, Aditya Tedjaseputra, Nicola Potter, Jelena Jovanovic, Amanda Gilkes, Leona Batten, Joanna Canham, Emily Hinson, Manohursingh Runglall, Phoebe Aucken, Panos Kottaridis, Jamie Cavenagh, Claire Arnold, Sylvie Freeman, Mike Dennis, Steven Knapper, Richard Dillon
Journal: Blood Advances
Blood Adv (2025) 9 (24): 6455–6466.
https://doi.org/10.1182/bloodadvances.2025017244
Published: 2025
Includes: Supplemental data
Journal Articles

Outcomes with single-agent gilteritinib for relapsed or refractory FLT3 -mutant AML after contemporary induction therapy

Free
Clinical Trials & Observations
Jad Othman, Angela Hwang, Maximillian Brodermann, Islam Abdallah, Kayleigh McCloskey, Paolo Gallipoli, Georgina Clarke, Raymond Dang, Jennifer Vidler, Pramila Krishnamurthy, Faisal Basheer, Anne-Louise Latif, Renuka Palanicawandar, Tom Taylor, Asra Khan, Victoria Campbell, Francesca Hogan, Alex Kanellopoulos, Kathryn Fleming, Angela Collins, Chris Dalley, Justin Loke, Scott Marshall, David Taussig, Sreetharan Munisamy, Eleana Loizou, Heba Yassin, Mike Dennis, Rui Zhao, Edward Belsham, Duncan Murray, Nicole Fowler, Jenny O'Nions, Anjum Khan, Rob Sellar, Richard Dillon
Journal: Blood Advances
Blood Adv (2024) 8 (21): 5590–5597.
https://doi.org/10.1182/bloodadvances.2024014017
Published: 2024
Includes: Supplemental data
Journal Articles

Venetoclax–based low intensity therapy in molecular failure of NPM1 -mutated AML

Free
Clinical Trials & Observations
Carlos Jimenez-Chillon, Jad Othman, David Taussig, Carlos Jimenez-Vicente, Alexandra Martinez-Roca, Ing Soo Tiong, Manish Jain, James Aries, Seda Cakmak, Steven Knapper, Daniel Tuyet Kristensen, Vidhya Murthy, Joy Zacharoula Galani, Charlotte Kallmeyer, Loretta Ngu, David Veale, Simon Bolam, Nina Orfali, Anne Parker, Cara Manson, Jane Parker, Thomas Erblich, Deborah Richardson, Katya Mokretar, Nicola Potter, Ulrik Malthe Overgaard, Anne Stidsholt Roug, Andrew H. Wei, Jordi Esteve, Martin Jädersten, Nigel Russell, Richard Dillon
Journal: Blood Advances
Blood Adv (2024) 8 (2): 343–352.
https://doi.org/10.1182/bloodadvances.2023011106
Published: 2024
Includes: Supplemental data
Journal Articles

A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial

Free
Clinical Trials & Observations
Jad Othman, Charlotte Wilhelm-Benartzi, Richard Dillon, Steve Knapper, Sylvie D. Freeman, Leona M. Batten, Joanna Canham, Emily L. Hinson, Julie Wych, Sophie Betteridge, William Villiers, Michelle Kleeman, Amanda Gilkes, Nicola Potter, Ulrik Malthe Overgaard, Priyanka Mehta, Panagiotis Kottaridis, Jamie Cavenagh, Claire Hemmaway, Claire Arnold, Mike Dennis, Nigel H. Russell
Journal: Blood Advances
Blood Adv (2023) 7 (16): 4539–4549.
https://doi.org/10.1182/bloodadvances.2023010276
Published: 2023
Includes: Supplemental data